FLGT - 10 Million Reasons I'm Not Selling Fulgent Genetics
A once-a-century pandemic has created a tough task for management teams trying to forecast the future. A wave of COVID-19 can shut down businesses, ramp up online commerce, and generally upend any well-meaning forecast.
That's what has happened with Fulgent Genetics (NASDAQ: FLGT) over the past year. The company -- and Wall Street -- seem to be aiming at a constantly moving target. But paying attention and crunching some numbers points to an opportunity for investors to get a leg up before the next quarter's results are released.
Image source: Getty Images.
For further details see:
10 Million Reasons I'm Not Selling Fulgent Genetics